CorpDev.Org
Deal Intelligence Platform & Services for Global M&A / PE
Big Deal
Blue Owl Weighs $30 Billion Asia Data Center Exit Amid Liquidity Pivot
Blue Owl Capital Inc. is exploring a full or partial divestment of the Asia-Pacific operations of its data center platform, Stack Infrastructure, according to people familiar with the matter. The potential transaction, which could be valued at...
The ‘Big Law’ Breach: Global Insider Trading Takedown Exposes M&A Information Vulnerabilities
TL;DR U.S. prosecutors unsealed a federal indictment on May 6, 2026, charging 30 individuals, including elite corporate attorneys, in a decade-long insider trading scheme that generated tens of millions in illicit profits. The scheme, allegedly led...
The Trillion-Dollar Pivot: Apollo Hits AUM Milestone Amid Record Fee Earnings
TL;DR Apollo Global Management reported crossing the $1 trillion assets under management (AUM) threshold in its Q1 2026 earnings, with total AUM reaching $1.026 trillion. This milestone was accompanied by record fee-related earnings (FRE) of $728...
Hubbell Bolsters Electrical Portfolio with $3 Billion Acquisition of NSI Industries
TL;DR Hubbell Incorporated announced a $3.0 billion all-cash agreement to acquire NSI Industries from Sentinel Capital Partners on May 4, 2026. The purchase price reflects a valuation of 15.5x NSI’s anticipated 2026 EBITDA, financed via a $2.8...
Santander UK’s £3 Billion TSB Acquisition: A Strategic Pivot Toward Retail Dominance
TL;DR Santander UK has acquired TSB from Spain’s Banco Sabadell for approximately £2.86 billion (€3.3 billion), creating the UK's third-largest provider of personal current accounts. The deal adds TSB's 5 million customers and is...
Explainers
Private Equity
International
International
Tech, Media & Telecom
Financial Services
Health & Life Sciences
Bayer Bolsters Ophthalmology Portfolio with $2.45 Billion Acquisition of Perfuse Therapeutics
TL;DR Bayer AG announced on May 6, 2026, its acquisition of Perfuse Therapeutics for up to $2.45 billion, including a $300 million upfront payment and $2.15 billion in milestones. The deal secures Perfuse's lead asset, PER-001, a Phase II...
UCB Acquires Candid Therapeutics for $2.2 Billion in High-Stakes Bet on ‘Immune Reset’
TL;DR Brussels-based biopharma UCB will acquire Candid Therapeutics for up to $2.2 billion, comprised of a $2.0 billion upfront cash payment and $200 million in milestones. The deal centers on Candid's lead asset, Cizutamig, a T-cell engager...
Sun Pharma Nears $12 Billion Acquisition of Organon: A New Frontier for Indian Pharma
TL;DR Mumbai-based Sun Pharmaceutical Industries Ltd. is finalizing a binding $12 billion offer for Organon & Co., marking the largest overseas acquisition in Indian pharma history. The deal is a strategic pivot for Sun Pharma, moving it from a...
Merck’s $6.7 Billion Bid for Terns Pharma: A Strategic Play for Metabolic Leadership
TL;DR Merck & Co. has launched a $6.7 billion all-cash unsolicited offer for Terns Pharma, a biotech firm specializing in small-molecule drug candidates for metabolic disorders like NASH. The acquisition is a strategic move to accelerate...
Alcon Abandons $430 Million Lensar Deal Citing Regulatory Drag; A Warning Shot for MedTech M&A
TL;DR Alcon terminated its agreement to acquire Lensar for up to $430 million on March 17, 2026, citing a protracted, year-long regulatory review by the Federal Trade Commission (FTC). The FTC opposed the deal, arguing it would eliminate direct...
